Solventum Co. (NYSE:SOLV) Shares Sold by Toronto Dominion Bank

Toronto Dominion Bank cut its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 22.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 55,317 shares of the company's stock after selling 15,779 shares during the quarter. Toronto Dominion Bank's holdings in Solventum were worth $3,654,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Clarity Asset Management Inc. acquired a new position in shares of Solventum during the 4th quarter valued at $25,000. Stonebridge Financial Group LLC acquired a new position in shares of Solventum in the 4th quarter worth $26,000. Raiffeisen Bank International AG acquired a new position in shares of Solventum in the 4th quarter worth $29,000. Crews Bank & Trust acquired a new position in shares of Solventum in the 4th quarter worth $32,000. Finally, Colonial Trust Co SC grew its holdings in shares of Solventum by 240.7% in the 4th quarter. Colonial Trust Co SC now owns 511 shares of the company's stock worth $34,000 after acquiring an additional 361 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Mizuho lifted their target price on Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a report on Monday, March 3rd. Piper Sandler upgraded Solventum from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $78.00 to $87.00 in a report on Monday. Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a report on Wednesday, March 5th. The Goldman Sachs Group lifted their price target on Solventum from $63.00 to $71.00 and gave the company a "sell" rating in a report on Monday, March 3rd. Finally, Bank of America lifted their price target on Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Solventum presently has an average rating of "Hold" and an average price target of $80.29.

Solventum Stock Performance

Shares of SOLV stock opened at $72.60 on Friday. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $12.56 billion and a price-to-earnings ratio of 33.61. The stock's fifty day simple moving average is $69.80 and its 200-day simple moving average is $71.32.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.19 by $0.15. The firm had revenue of $2.07 billion for the quarter, compared to analyst estimates of $2.02 billion. Solventum's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.08 EPS. On average, sell-side analysts predict that Solventum Co. will post 6.58 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.